Semaglutide, the active ingredient in medicines such as Ozempic and Wegovy, may have an unexpected connection with respiratory health. New real-world research presented at the European Respiratory Society (ERS) Congress in Barcelona found that semaglutide use was associated with nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups.
A Possible Link Between GLP-1 Drugs and Lung Health
GLP-1 receptor agonists are primarily used for type 2 diabetes and obesity. Their effects on appetite, blood sugar and body weight are well established, but researchers are increasingly investigating whether their metabolic and potentially anti-inflammatory effects could also influence diseases outside the traditional treatment areas.
The new research analyzed UK electronic health records, comparing people receiving GLP-1 medicines with similar patients prescribed sulfonylurea diabetes drugs. Four parallel studies included roughly 20,000–22,000 people each.
Among the GLP-1 medicines studied, semaglutide showed the strongest association with fewer respiratory attacks, particularly among people with asthma.
Why Could Obesity Matter for Asthma?
The connection may partly involve the relationship between obesity, metabolic dysfunction and airway disease.
Excess body fat can affect breathing mechanics and is associated with inflammation and changes in airway function. Recent research has also highlighted a relationship between obesity and small-airway dysfunction, suggesting that respiratory consequences of excess weight may be more complex than simply reduced lung capacity.
This makes the possibility of metabolic treatments influencing respiratory outcomes particularly interesting.
But Semaglutide Is Not an Asthma Treatment
The researchers emphasize an important limitation: this was real-world observational research, not a randomized clinical trial designed to prove that semaglutide prevents asthma attacks.
That means the findings show an association, not definitive cause and effect. People should not start Ozempic, Wegovy or another GLP-1 medicine specifically to treat asthma or COPD. The ERS says clinical trials are needed to determine whether the apparent respiratory benefit is real and what mechanism might explain it.
What Comes Next?
Future studies could examine whether GLP-1 therapies directly affect lung inflammation, lung function, asthma symptoms, COPD exacerbations and quality of life.
The research also adds to a broader shift in obesity medicine: scientists are increasingly examining whether treating metabolic dysfunction can produce benefits beyond the number on the weighing scale.
Bottom Line
The latest evidence suggests that semaglutide users with asthma had nearly 40% fewer asthma attacks, while COPD flare-ups were associated with a reduction of around 20%. These are intriguing findings, but they need confirmation through controlled clinical trials before GLP-1 drugs can be considered part of respiratory disease treatment.
Medical disclaimer: This article is for educational purposes only. Semaglutide is not currently an asthma or COPD treatment. Do not start, stop or change prescription medication based on this research without consulting a qualified healthcare professional.
Source: European Respiratory Society
